ArticleOncology reports2020
METTL14 promotes the migration and invasion of breast cancer cells by modulating N6‑methyladenosine and hsa‑miR‑146a‑5p expression.
Article in Oncology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 119 citations in OpenAlex.
- Effects of Isorhapontigenin on Cell Viability, Colony-Forming Efficiency, and Ferroptosis via Methyltransferase-Like 14-Mediated mMolecular carcinogenesis · 2026Article
- Regulatory roles of N6-methyladenosine methylation factors in melanoma invasion and metastasis (Review).Oncology letters · 2026Review
- MicroRNA and Alzheimer's disease: Diagnostic biomarkers and potential therapeutic targets.Neural regeneration research · 2026Article
- Methylation marks breast cancer metastasis: The roles of mThe Journal of biological chemistry · 2026Review
- Machine Learning-Based Integration Unveils RNA Methylation Regulator-Related Immune-Derived Gene Signatures in Ruptured Intracranial Aneurysm.Biomedicines · 2026Article
- miR-30c-2-3p Regulates METTL14 Expression and Inhibits Cell Migration in Breast Cancer.Current issues in molecular biology · 2026Article
- m⁶A-Modified hsa_circ_0002694 facilitates OSCC progression via the METTL14/YTHDC1/miR-616-3p/c-Myc axis.Head & face medicine · 2026Article
- The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification.PloS one · 2026Article
- mFrontiers in immunology · 2026Article
- MicroRNA chemical modifications in post-transcriptional gene silencing and human diseases.Molecular therapy. Nucleic acids · 2025Review
- Research progress on m6A RNA methylation modification in human reproduction related diseases.European journal of medical research · 2025Review
- Functional and clinical significance of the RNA mNPJ breast cancer · 2025Article
- A multifaceted investigation into the impact of m6A methylation-related genes on pancreatic cancer, integrating insights from various databases and foundational experimental research.Annals of medicine and surgery (2012) · 2025Article
- Targeting RNA adenosine editing and modification enzymes for RNA therapeutics.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Analysis of the mRNA modification machinery alterations in breast cancer through the SCAN-B cohort.NAR cancer · 2025Article
- RNA mCell investigation · 2025Article
- METTL14 suppresses the migration and invasion of hepatocellular carcinoma cells by m6A methylation of RPLP2.Scientific reports · 2025Article
- Research Progress on Natural Products That Regulate miRNAs in the Treatment of Osteosarcoma.Biology · 2025Review
- Divergent roles of mNature communications · 2025Article
- Influence of RNA Methylation on Cancerous Cells: A Prospective Approach for Alteration of In Vivo Cellular Composition.Advances in experimental medicine and biology · 2025Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer‑related death among women worldwide. Evidence indicates that posttranscriptional N6‑methyladenosine (m6A) modification modulates BC development. In the present study, we assessed BC and normal tissues to investigate this connection. RNA m6A levels were determined by methylation quantification assay. The effects of methyltransferase‑like 14 (METTL14) gain‑of‑expression or co‑transfection with an m6A inhibitor on cell migration and invasion abilities were determined by Transwell assays. The levels of differentially expressed (DE) miRNAs were verified by real‑time quantitative PCR (RT‑qPCR). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes analyses (KEGG) were performed to analyze potential function of target genes of the DE miRNAs. The effects of candidate miRNAs modulated by METTL14 on cell migration and invasion abilities were confirmed by Transwell assays. We demonstrated that m6A methyltransferase METTL14 was significantly upregulated in BC tissues compared with normal tissues. METTL14 gain‑ and loss‑of‑expression regulated m6A levels in MCF‑7 and MDA‑MB‑231 cells. The cell function assays revealed that METTL14 overexpression enhanced the migration and invasion capacities of BC cells. Moreover, treatment with the m6A inhibitor suppressed this enhanced cell migration and invasion. Additionally, aberrant expression of METTL14 reshaped the miRNA profile in BC cell lines. The remodeled DE miRNA/mRNA network was found to be most enriched in cancer pathways, and DE miRNAs were enriched in cell adhesion terms. hsa‑miR‑146a‑5p modulated by METTL14 promoted cell migration and invasion. METTL14 modulates m6A modification and hsa‑miR‑146a‑5p expression, thereby affecting the migration and invasion of breast cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.